Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase II Study of Lapatinib in Combination With Vinorelbine in Subjects With ErbB2 Amplified Recurrent and Metastatic Breast Cancer

NCT01128543 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01128543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01128543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase II Study of Lapatinib in Combination With Vinorelbine in Subjects With ErbB2 Amplified Recurrent and Metastatic Breast Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
March 31, 2012
Enrollment
29 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cancer